for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Codexis, Inc.

CDXS.OQ

Latest Trade

14.78USD

Change

-0.12(-0.81%)

Volume

11,861

Today's Range

14.75

 - 

14.84

52 Week Range

12.69

 - 

23.01

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
14.90
Open
14.76
Volume
11,861
3M AVG Volume
10.33
Today's High
14.84
Today's Low
14.75
52 Week High
23.01
52 Week Low
12.69
Shares Out (MIL)
58.36
Market Cap (MIL)
869.54
Forward P/E
-65.49
Dividend (Yield %)
--

Next Event

Codexis Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Codexis Reports Q2 2019 Results

Codexis Inc - Announces Signing Of A Codeevolver Platform Agreement With Novartis

Codexis Entered Into Platform Technology Transfer And License Agreement With Novartis

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Codexis, Inc.

Codexis, Inc. is a protein engineering company. The Company is engaged in the development of biocatalysts for the commercial manufacture of pharmaceuticals and fine chemicals. The Company operates through its two segments, such as the performance enzymes and novel biotherapeutics. It provides enzyme optimization services from small scale through to commercial quantities and also develops biocatalyst products. It is also engaged in the development of manufacturing processes for active pharmaceutical ingredients, fine chemicals and food ingredients. Its CodeEvolver is a protein engineering technology platform and products in the pharmaceuticals market. The Company serves various industries, including food and food ingredients, animal feed, flavors, fragrances, and agricultural chemical.

Industry

Chemical Manufacturing

Contact Info

200 Penobscot Dr

+1.650.4218100

https://www.codexis.com/

Executive Leadership

Bernard J. Kelley

Independent Chairman of the Board

John J. Nicols

President, Chief Executive Officer, Director

Ross Taylor

Chief Financial Officer, Senior Vice President

Laurie Heilmann

Senior Vice President of Business Development and Marketing

Thomas R. Baruch

Independent Director

Key Stats

1.80 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.1K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-0.210

2017

-0.500

2018

-0.210

2019(E)

-0.228
Price To Earnings (TTM)
--
Price To Sales (TTM)
14.27
Price To Book (MRQ)
8.75
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.19
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-14.92
Return on Equity (TTM)
-12.65

Latest News

BRIEF-Codexis Reports Q1 Loss Per Share $0.10

* Q1 EARNINGS PER SHARE VIEW $-0.12 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Porton Fine Chemicals signs strategic agreement with Codexis on enzymatic related business

* Says it signed strategic agreement with U.S. company Codexis Inc on enzymatic related business

BRIEF-Codexis Announces Proposed Public Offering Of Common Stock

* CODEXIS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Codexis Q4 Non-Gaap Earnings Per Share $0.06

* CODEXIS REPORTS 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

BRIEF-Telemark Asset Management LLC reports 6.72 pct passive stake in Codexis as of Nov 10

* Telemark Asset Management LLC reports 6.72 percent passive stake in Codexis Inc as of November 10 - SEC Filing Source text: [http://bit.ly/2AYhX8Y] Further company coverage:

BRIEF-Codexis Q3 non-gaap loss per share $0.17

* Codexis reports financial results for the third quarter of 2017

BRIEF-Codexis Inc, Nestlé Health Science enter strategic collaboration​

* Codexis Inc - co, Nestlé Health Science enter strategic collaboration

BRIEF-Codexis Q2 loss per share $0.13

* Codexis reports financial results for the second quarter of 2017

BRIEF-Codexis ‍wins summary judgment of patent infringement against EnzymeWorks​

* Codexis Inc - obtains court order awarding summary judgment of patent infringement against EnzymeWorks

BRIEF-Codexis, effective as of June 30, entered into loan, security agreement with Western Alliance Bank

* Codexis Inc - effective as of june 30, 2017 co entered into a loan and security agreement with western alliance bank

BRIEF-Codexis reports Q1 non-GAAP loss per share $0.13

* Codexis reports financial results for the first quarter of 2017

BRIEF-Codexis announces pricing of public offering of common stock

* Codexis announces pricing of public offering of common stock

BRIEF-Codexis signs second multi-year agreement in food industry with Tate & Lyle

* Codexis signs second multi-year agreement in food industry with Tate & Lyle

BRIEF-Codexis Q4 loss per share $0.13

* Codexis reports 2016 fourth quarter and full year financial results

BRIEF-Codexis reports Q3 adj. earnings per share $0.09

* Codexis reports financial results for the third quarter of 2016

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up